Mayne Pharma entered into an agreement with TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX: MYX) announced that it had entered into a transaction contract and related license agreement for a portfolio of three branded on-market women’s health products from TherapeuticsMD for a total consideration of US$140 million. The deal comprises payment for acquired working capital and contingent payments based on achieving certain sales-based milestones and sales-based royalties. 

Under the contract, the company will solely license ANNOVERA, IMVEXXY, BIJUVA, and the BocaGreenMD and vitaMedMD lines of prenatal vitamins and purchase selected assets comprising inventory and regulatory filings to support the operation and commercialisation of the portfolio. The contract will help to improve Mayne Pharma’s position in the US women’s health market. The company anticipates to complete the transaction on or before 30 December 2022.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com